跳至主要内容
临床试验/NCT00221546
NCT00221546已完成2 期

Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic Fibrosis

University Hospital, Ghent1 个研究点 分布在 1 个国家目标入组 17 人开始时间: 2007年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
17
试验地点
1
主要终点
Clinical evolution: weight, height, pulmonary function and infection frequency before the study start and during the 2 years of the study

研究概览

简要总结

Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis

详细描述

Investigation of the influence of giving DHA-rich supplement versus placebo on DHA-status and health evolution of patients with cystic fibrosis

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Single Group
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
6 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Delta F 508 homozygote
  • Stable clinical situation

排除标准

  • 未提供

研究组 & 干预措施

DHA-rich supplement

Active Comparator

干预措施: Giving DHA-rich supplement (Drug)

Placebo

Placebo Comparator

干预措施: Giving DHA-rich supplement (Drug)

结局指标

主要结局

Clinical evolution: weight, height, pulmonary function and infection frequency before the study start and during the 2 years of the study

时间窗: before the study start and during the 2 years of the study

次要结局

  • Oxidative stress status(during the 2 years of the study)
  • Evolution of the fatty acid profile(during the 2 years of the study)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验